CBLL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ceribell Inc (CBLL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has shown strong revenue growth, expanded its market reach, and received FDA clearance for innovative products, which are significant positive catalysts. While the technical indicators are neutral, the long-term growth prospects and positive analyst sentiment make it a compelling investment opportunity.
The MACD is below 0 and negatively contracting, RSI is neutral at 37.826, and moving averages are converging. The stock is trading near its support level (S1: 18.306), indicating limited downside risk in the short term.
FDA 510(k) clearance for delirium monitoring solution, expanding the total addressable market from $2 billion to $3.5 billion.
Strong Q4 2025 revenue growth of 34% YoY, surpassing expectations.
Anticipated 2026 revenue growth of 25%-29%.
Increased commercial infrastructure and active accounts, indicating strong operational growth.
Widened net loss in Q4 2025 to $13.53 million.
Gross margin slightly declined YoY to 87.33%.
In Q4 2025, revenue increased by 33.72% YoY to $24.78 million, while net income improved slightly but remained negative at -$13.53 million. EPS improved to -$0.36, up 2.86% YoY. Gross margin dropped slightly to 87.33%. The company anticipates 2026 revenue growth of 25%-29%, reflecting strong demand.
Analysts maintain a Buy rating with a slightly lowered price target of $28 from $30, citing conservative guidance but multiple growth drivers. Previous upgrades were driven by FDA clearance and strong sector demand, indicating continued optimism about the company's prospects.
